Ondansetron QT prolongation — FRCA Primary MCQ

Instant feedback + full explanation. One question, done properly.

HardPharmacologyOndansetron QT prolongationFRCA Primary

A patient with congenital long-QT syndrome needs antiemetic prophylaxis. Which drug most clearly adds QT-prolongation risk?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Ondansetron

The best answer is “Ondansetron”. MHRA advice identifies dose-dependent QTc prolongation and torsades de pointes as recognised risks of ondansetron, and advises avoiding it in congenital long-QT syndrome. The other listed drugs are recognised perioperative antiemetic options but should still be chosen in light of the patient’s full clinical context.

Reference: MHRA, Ondansetron for intravenous use: dose-dependent QT prolongation: https://www.gov.uk/drug-safety-update/ondansetron-for-intravenous-use-dose-dependent-qt-interval-prolongation